Table 4.
Adjusted HRs comparing combination therapy with monotherapy for each end point at prespecified eGFR values
| End Point | HRa (95% CI) | Interaction P Valuea |
|---|---|---|
| Primary composite end point | ||
| Death from cardiovascular disease, major coronary event, or nonfatal stroke, ml/min per 1.73 m2 | 0.04 | |
| eGFR=45 | 0.87 (0.78 to 0.98) | |
| eGFR=60 | 0.88 (0.82 to 0.95) | |
| eGFR=75 | 0.91 (0.84 to 0.99) | |
| eGFR=90 | 0.99 (0.92 to 1.06) | |
| eGFR=105 | 1.08 (0.95 to 1.22) | |
| Overall effect | 0.94 (0.89 to 0.99) | |
| Secondary composite end points | ||
| All-cause mortality, major coronary event, or nonfatal stroke, ml/min per 1.73 m2 | 0.25 | |
| eGFR=45 | 0.90 (0.82 to 0.99) | |
| eGFR=60 | 0.92 (0.86 to 0.98) | |
| eGFR=75 | 0.95 (0.88 to 1.02) | |
| eGFR=90 | 0.98 (0.92 to 1.05) | |
| eGFR=105 | 1.02 (0.91 to 1.15) | |
| Overall effect | 0.95 (0.90 to 1.00) | |
| Death from cardiovascular disease, nonfatal MI, or nonfatal stroke, ml/min per 1.73 m2 | 0.07 | |
| eGFR=45 | 0.79 (0.70 to 0.90) | |
| eGFR=60 | 0.87 (0.79 to 0.94) | |
| eGFR=75 | 0.93 (0.84 to 1.03) | |
| eGFR=90 | 0.96 (0.87 to 1.05) | |
| eGFR=105 | 0.99 (0.83 to 1.17) | |
| Overall effect | 0.95 (0.90 to 1.00) | |
| Tertiary composite end point | ||
| All-cause mortality, ml/min per 1.73 m2 | 0.06 | |
| eGFR=45 | 0.92 (0.81 to 1.05) | |
| eGFR=60 | 1.05 (0.95 to 1.16) | |
| eGFR=75 | 1.12 (0.99 to 1.25) | |
| eGFR=90 | 1.01 (0.89 to 1.14) | |
| eGFR=105 | 0.91 (0.73 to 1.13) | |
| Overall effect | 0.99 (0.91 to 1.07) |
Adjusted for age, sex, race, weight, family history of coronary artery disease, diabetes, hypertension, smoking status, history of angina, prior MI, prior percutaneous coronary intervention, prior coronary artery bypass graft, history of peripheral artery disease, prior stroke, prior congestive heart failure, percutaneous coronary intervention or catheterization at qualifying event, prior atrial fibrillation, baseline Killip class, systolic BP, heart rate, baseline medications (β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, aspirin, or statin therapy), geographic region, qualifying event diagnosis, electrocardiogram changes (transient ST elevation, ST depression, or T-wave changes), hemoglobin at randomization, and baseline LDL, HDL, and triglycerides at time of qualifying event.